Mid-term and long-term outcomes of functional mitral insufficiency interventional treatment in patients with cardiomyopathy

O. Shatova, T. Denisevich, E. Kurlyanskaya, O. Poloneckij, T. Asmalouskaya

T he article presents the outcomes of treatment of patients with cardiomyopathy and pronounced functional mitral insufficiency 6, 12 and 24 months after MitraClip device implantation. We observed that 6 months after the intervention, there was regression of left heart chamber remodeling, as well as positive dynamics of right ventricular ejection fraction and pulmonary artery pressure against the background of mitral valve improvement. The achieved effect of improved intracardiac hemodynamics persisted in 12 months after mitral valve clipping. After 12 months, there were signs of left ventricular remodeling without significant changes in valve characteristics and left atrial parameters. During the first 6 to 12 months after MitraClip implantation, the distance walked in the 6-minute walk test and peak oxygen consumption increased, with retention of high values of these indicators in 24 months of follow-up.

keywords: cardiomyopathy, mitral insufficiency, MitraClip device.

for references: O. Shatova, T. Denisevich, E. Kurlyanskaya, O. Poloneckij, T. Asmalouskaya. Mid-term and long-term outcomes of functional mitral insufficiency interventional treatment in patients with cardiomyopathy. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2023, vol. 7, no. 1, pp. 1835–1844.

1. Baumgartner H., Praz F., Milojevic M., et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Rev Esp de Cardiol, 2017, vol. 71(2), pp. 110.
2. Feldman T., Kar S., Rinaldi M., Fail P., Hermiller J., Smalling R., Whitlow P.L., Gray W., Low R., Herrmann H.C., Lim S., Foster E., Glower D., EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009, vol. 54(8), pp. 686-694. doi: 10.1016/j.jacc.2009.03.077.
3. Feldman T., Kar S., Elmariah S., Smart S.C., Trento A., Siegel R.J., Apruzzese P., Fail P., Rinaldi M.J., Smalling R.W., Hermiller J.B., Heimansohn D., Gray W.A., Grayburn P.A., Mack M.J., Lim D.S., Ailawadi G., Herrmann H.C., Acker M.A., Silvestry F.E., Foster E., Wang A., Glower D.D., Mauri L., EVEREST II Investigators. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol, 2015, vol. 66(25), pp. 2844-2854. doi: 10.1016/ j.jacc.2015.10.018 28.
4. Glower D.D., Kar S., Trento A., Lim D.S., Bajwa T., Quesada R., Whitlow P.L., Rinaldi M.J., Grayburn P., Mack M.J., Mauri L., McCarthy P.M., Feldman T. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol, 2014, vol. 64(2), pp. 172-181. doi: 10.1016/j.jacc.2013.12.062.
5. Stone G.W., Lindenfeld J., Abraham W.T., Kar S., Lim D.S., Mishell J.M., Whisenant B., Grayburn P.A., Rinaldi M., Kapadia S.R., Rajagopal V., Sarembock I.J., Brieke A., Marx S.O., Cohen D.J., Weissman N.J., Mack M.J., COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med, 2018, vol. 379(24), pp. 2307-2318. doi: 10.1056/NEJMoa1806640.
6. Obadia J.-F., Messika-Zeitoun D., Leurent G., Iung B., Bonnet G., Piriou N., Lefèvre T., Piot C., Rouleau F., Carrié D., Nejjari M., Ohlmann P., Leclercq F., Saint Etienne C., Teiger E., Leroux L., Karam N., Michel N., Gilard M., Donal E., Trochu J.-N., Cormier B., Armoiry X., Boutitie F., Maucort-Boulch D., Barnel C., Samson G., Guerin P., Vahanian A., Mewton N., MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med, 2018, vol. 379(24), pp. 2297-2306. doi: 10.1056/NEJMoa1805374.
7. Adamo M., Godino C., Giannini C., Scotti A., Liga R., Curello S., Fiorina C., Chiari E., Chizzola G., Abbenante A., Visco E., Branca L., Fiorelli F., Agricola E., Stella S., Lom-bardi C., Colombo A., Petronio A.S., Metra M., Ettori F. Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry. Eur J Heart Fail, 2019, vol. 21(2), pp. 196-204. doi: 10.1002/ejhf.1343.
8. Geis N.A., Puls M., Lubos E., Zuern C.S., Franke J., Schueler R., von Bardeleben R.S., Boekstegers P., Ouarrak T., Zahn R., Ince H., Senges J., Katus H.A., Bekeredjian R. Safety and efficacy of MitraClipTM therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail, 2018, vol. 20(3), pp. 598-608. doi: 10.1002/ejhf.910.
9. Neuss M., Schau T., Schoepp M., Seifert M., Holschermann F., Meyhofer J., Butter C. Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure. Eur J Heart Fail, 2013, vol. 15(7), pp. 786-795. doi: 10.1093/eurjhf/hfs214.
10. Swaans M.J., Bakker A.L.M., Alipour A., Post M.C., Kelder J.C., de Kroon T.L., Eefting F.D., Rensing B.J.W.M., Van der Heyden J.A.S. Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. JACC Cardiovasc Interv, 2014, vol. 7(8), pp. 875-881. doi: 10.1016/ j.jcin.2014.01.171.
11. Velazquez E.J., Samad Z., Al-Khalidi H.R., Sangli C., Grayburn P.A., Massaro J.M., Stevens S.R., Feldman T.E., Krucoff M.W. The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: a propensity-matched comparison. Am Heart J, 2015, vol. 170(5), pp. 1050-1059.e3. doi: 10.1016/j.ahj.2015.08.004.
12. Bokeriya L.A., Goluhova E.Z., Kochladze N.G., Aleksandrova S.A., Makarenko V.N., Serov R.A. Prognosticheskoe i klinicheskoe znachenie markerov remodelirovaniya predserdij pri fibrillyacii predserdij [Prognostic and clinical significance of atrial remodeling markers in atrial fibrillation]. Annaly aritmologii, 2004, no. 1, pp. 71–77. (in Russian).
13. Silbiger, J.J. Novel pathogenetic mechanisms and structural adaptations in ischemic mitral regurgitation. J Am Soc Echocardiogr, 2013, vol. 26(10), pp. 1107–1117. doi: 10.1016/j.echo.2013.07.003.
14. Silbiger, J.J. Anatomy, mechanics, and pathophysiology of the mitral annulus. Am Heart J, 2012, vol. 164(2), pp. 163–176. doi: 10.1016/j.ahj.2012.05.014.
15. Andrianova A.M., Saidova M.A. Ishemicheskaya mitralnaya nedostatochnost’: sovremennye kriterii ocenki po dannym transtorakalnoj ekhokardiografii [Ischemic mitral regurgitation: modern criteria of evaluation using transthoracic echocardiography]. Lechebnoe delo (Moscow), 2015, no. 3, pp. 93–102. (in Russian).
16. Kopeva K.V., Grakova E.V., Teplyakov A.T. Novye markery serdechnoj nedostatochnosti: znachenie dlya diagnostiki i prognozirovaniya NT-proBNP i interlejkinovyh receptorov – chlenov semejstva ST2 [New biomarkers of heart failure: diagnostic and prognostic value of NT-proBNP and interleukin receptor family member ST2]. Kompleks. problemy serdechno-sosudistyh zabolevanij, 2018, vol. 7(1), 94–101. (in Russian).
17. Wood P. An appreciation of mitral stenosis – I. Clinical features. Br Med J, 1954, vol. 1(4870), pp. 1113–1124. doi: 10.1136/bmj.1.4870.1051
18. Antunes M.J., Barlow J.B. Management of tricuspid valve regurgitation. Heart, 2007, vol. 93(2), pp. 271–276. doi: 10.1136/hrt.2006.095281.

View full article

Download this article

File extension: pdf (694.37 KB)

→ Главная → 2023 Том 7, №1